Careers Customer Login Contact Us

Molecular Diagnostics

Molecular diagnostic laboratories are at the forefront of diagnostic advancements and deal with a diverse range of issues from complex reimbursement requirements, to how to properly handle their rapid growth, to how to best report and collaborate on test findings.

Molecular Diagnostics Lab Solutions

Revenue Cycle Management

XiFin RPM helps high-growth diagnostic laboratories address this issue by utilizing a sophisticated rules-based workflow to automate the claims process, thus requiring very little manual intervention, and enabling laboratories to more easily scale their billing operations to match their rapid growth.

Learn More

Laboratory Information System

XiFin LIS provides a molecular diagnostics platform that supports chart and image import, data integration, logic-driven customized report templates, batch workflows for PCR, and more.

Learn More

Healthcare Informatics

VisualStrata uniquely integrates and visualizes clinical, diagnostic, and financial data, enabling healthcare professionals to create shared data models, gain insights, make better decisions, improve outcomes, and create new revenue streams.

Learn More

Spotlight: XiFin LIS

XiFin LIS for Molecular Diagnostics

Reporting, data management, and integrations are vital components of an effective MDx laboratory LIS. XiFin LIS for Molecular Diagnostics not only meets these needs, it exceeds them.

Rapid growth in molecular diagnostic (MDx) testing and complementary services is being driven by the advancement in human genotyping and a transition to a value-based care model. This expansion is creating data and workflow management, reporting, compliance, and testing modality reimbursement policy issues that must be solved for today’s MDx labs to thrive. 

Whether your facility is an early-stage MDx laboratory, an established lab experiencing growth, or a mature lab looking to gain efficiencies and develop new revenue streams, XiFin LIS is the perfect solution.

View Datasheet

XiFin LIS for Genomics

Accessioning, billing integration, and workflow automation are all vital components of an effective PGx/NGS laboratory LIS. XiFin LIS Anywhere for Genomics not only meets these needs, it exceeds them.

The frequency and cost of adverse drug events (ADEs), coupled with a shift towards a value-based healthcare model is forcing a rapid change in the healthcare landscape. As a result, pharmacogenomics (PGx) and next-generation sequencing (NGS) are seeing increased utility and application in the clinical environment.

To take advantage of this growth opportunity, PGx and NGS focused laboratories must be equipped to solve the data and workflow management, reporting, compliance, and testing modality reimbursement policy issues that are being created.

Whether your facility is an early-stage lab, an established lab experiencing growth, or a mature lab looking to gain efficiencies and develop new revenue streams, XiFin LIS Anywhere is the perfect solution.

Learning from Payor Behavior to increase Appeal Success

Learning from Payor Behavior to increase Appeal Success

The XiFin Advantage

Stay In Front Of Change

Whether it’s managing the typical reimbursement challenges faced by all laboratories, or addressing longstanding difficulties such as modifier and consolidation rules, new payor requirements and split jurisdiction issues, we’ve been on the forefront of these issues and have designed XiFin RPM to quickly adjust to the needs of our clients.

Adjust to Rapid Growth

Molecular testing capabilities have delivered hyper-growth to many laboratories, leaving these businesses' operations overwhelmed by the depth and breadth of the claims volume. Likewise, these laboratories have often struggled to implement automation and workflow optimization that can match the complexity and volumes that they are experiencing


XiFin LIS clients have successfully scaled their laboratory businesses by over 500% while on the system.


As a proven leader in the molecular diagnostic testing market, XiFin RPM processes over 60% of all molecular testing claims nationwide, including those from small, high-growth molecular diagnostic companies as well as industry leaders like Myriad and Clarient.


XiFin LIS has the ability to integrate with 90% of the top EMR systems while retaining historic data with no degradation of performance.

Molecular Diagnostics Success Stories

Commercialization & Reimbursement Consulting

XiFin provides a comprehensive range of reimbursement and commercialization consulting services for molecular diagnostics.

We help early stage companies bring new molecular diagnostics and advanced diagnostic device concepts to market effectively, as well as guide mature companies on how to improve reimbursement processes to increase profitability. We also work with investors looking to inject capital in molecular diagnostics and medical device ventures with high potential.

It’s Easy To Get Started

Commercialization and Reimbursement Consulting offers flexibility to customize an engagement that addresses your needs and your budget. We can work with you on a specific need, such as developing a commercialization strategy, or we can work with you on an ongoing basis to ensure that our clients are always up to date on any issues that may impact their business, including market and regulatory changes. We help you stay ahead of change and ensure that you have the operational agility to handle rapid growth.

Complimentary Webinar

Breaking News on Trends and Denials Involving Lab Test Claims

Available On-Demand

Hosted By:

Market Resources

A CEO's Guide to Molecular Diagnostic Reimbursement: Navigating the Many Challenges of Reimbursement and Commercialization

This white paper breaks down the many elements that go into crafting reimbursable and commercialized molecular diagnostics programs.

A Pay-For-Value, Data-Driven Approach for the Coverage of Innovative Genetic Tests

This paper proposes an alternative model for coverage determination that builds upon programs like MolDx by Palmetto and capitalizes on the knowledge gleaned from early registries, addresses the key underlying financial motivations that drive coverage determinations, and advocates for a shift to a Pay-For-Value model based on risk sharing between parties.